We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

178 hedge funds and large institutions have $1.96B invested in Rocket Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $3.15M

48% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 50

1.56% less ownership

Funds ownership: 102.06% → 100.51% (-1.6%)

4% less funds holding

Funds holding: 186 → 178 (-8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less capital invested

Capital invested by funds: $2.48B → $1.96B (-$522M)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

Holders
178
Holders Change
-8
Holders Change %
-4.3%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
74
Reduced
50
Closed
27
Calls
$5.17M
Puts
$3.15M
Net Calls
+$2.02M
Net Calls Change
-$15.1M

Top Buyers

1
WP
Woodline Partners
California
+$12.9M
2
EC
EcoR1 Capital
California
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$8M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$7.9M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$34M
2
State Street
State Street
Massachusetts
-$32.5M
3
LGM
Logos Global Management
California
-$21.8M
4
PA
Perceptive Advisors
New York
-$12.7M
5
CAM
Cormorant Asset Management
Massachusetts
-$8.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
151
Carson Wealth (CWM LLC)
Nebraska
$27K +$322 +14 +1%
US Bancorp
152
US Bancorp
Minnesota
$23.3K -$25.1K -1,095 -50%
S
153
SignatureFD
Georgia
$18.4K +$459 +20 +2%
Pacer Advisors
154
Pacer Advisors
Pennsylvania
$14.4K -$19.7K -859 -56%
NS
155
NBC Securities
Alabama
$9K – – –
Osaic Holdings
156
Osaic Holdings
Arizona
$8.51K +$3.19K +139 +54%
SAM
157
Smartleaf Asset Management
Massachusetts
$8.21K +$8.8K +383 New
UB
158
UMB Bank
Missouri
$8.18K -$643 -28 -7%
Daiwa Securities Group
159
Daiwa Securities Group
Japan
$7K – – –
HNB
160
Huntington National Bank
Ohio
$4.91K -$5.72K -249 -52%
Jones Financial Companies
161
Jones Financial Companies
Missouri
$4.74K +$5.05K +220 New
LC
162
Lindbrook Capital
California
$4.67K +$988 +43 +25%
BL
163
BFSG LLC
California
$4.31K +$4.59K +200 New
MAM
164
Meeder Asset Management
Ohio
$3.83K +$4.09K +178 New
QCG
165
Quadrant Capital Group
Ohio
$2.24K – – –
FFA
166
Farther Finance Advisors
California
$2.17K – – –
ACM
167
ADAR1 Capital Management
Texas
$2.15K +$2.3K +100 New
PWMG
168
Private Wealth Management Group
New Jersey
$1.49K – – –
GI
169
GAMMA Investing
California
$1.12K +$322 +14 +37%
IC
170
Innealta Capital
Texas
$1.05K +$1.13K +49 New
Lazard Asset Management
171
Lazard Asset Management
New York
$1K -$24.7K -1,076 -93%
SFC
172
Strategic Financial Concepts
Texas
$895 +$505K +21,981 New
National Bank of Canada
173
National Bank of Canada
Quebec, Canada
$720 +$804 +35 New
EWM
174
Evermay Wealth Management
Virginia
$539 – – –
FHA
175
First Horizon Advisors
Tennessee
$516 – – –
5 6
7
8 9

RCKT Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2024, worth a combined $1.96B — down 21% from $2.48B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RCKT and 21 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 74 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $12.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $34M sold.

  • 178 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2024, down from 186 in Q1 2024.
  • Funds reported $1.96B of Rocket Pharmaceuticals stock for Q2 2024, down 21% quarter-over-quarter.
  • 21 funds opened new Rocket Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
  • The largest Rocket Pharmaceuticals buyer in Q2 2024 was Woodline Partners, an estimated $12.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2024 was Avoro Capital Advisors, an estimated $34M sold.

Based on aggregated 13F filings for Q2 2024.